Menu
Recruiting NCT07328035

Remission in Adults With Severe Asthma in Thailand

— Observational Severe Asthma Asthma Control Level

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires, Spirometry, Fractional exhaled nitric oxide (FeNO) test, Blood eosinophil count (BEC).
Who it may be relevant to
Registry conditions: Severe Asthma, Asthma Control Level. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Thailand
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The goal of this observational study is to determine the prevalence of remission among adults with severe asthma, as well as the factors associated with remission in Thailand. The main question the study aims to answer is: What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete questionnaires on asthma symptoms and undergo pulmonary function testing and a blood test once.

Detailed description

This study is a cross-sectional study. Thai patients aged 18 years or older with severe asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).

Interventions

  • Other Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires
    GINA and ACT are questionnaires used to assess the level of asthma control.
  • Diagnostic test Spirometry
    Spirometry is a tool used to assess pulmonary function.
  • Diagnostic test Fractional exhaled nitric oxide (FeNO) test
    FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
  • Diagnostic test Blood eosinophil count (BEC)
    BEC is a tool used to assess eosinophilic inflammation and asthma remission.

Primary outcome measures

  • Prevalence rate of severe asthma remission [Time frame: The beginning of the study]
Secondary outcome measures (3)
  • Association of clinical characteristics with severe asthma remission [Time frame: The beginning of the study]
  • Association of lung function with severe asthma remission [Time frame: The beginning of the study]
  • Association of inflammatory biomarkers with severe asthma remission [Time frame: The beginning of the study]

Eligibility criteria

Inclusion criteria

  • severe asthma
  • age 18 years or older

Exclusion criteria

  • inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Thailand · 1 center
  • Narongkorn Saiphoklang — Pathum Thani

Publications

  • McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. Print 2023 Dec. PMID 37857423
  • Tupper OD, Hakansson KEJ, Ulrik CS. Remission and Changes in Severity Over 30 Years in an Adult Asthma Cohort. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1595-1603.e5. doi: 10.1016/j.jaip.2020.11.013. Epub 2020 Nov 19. PMID 33220516
  • Chipps BE, Lugogo N, Carr W, Zhou W, Patel A, Carstens DD, Trudo F, Ambrose CS. On-treatment clinical remission of severe asthma with real-world longer-term biologic use. J Allergy Clin Immunol Glob. 2024 Oct 30;4(1):100365. doi: 10.1016/j.jacig.2024.100365. eCollection 2025 Feb. PMID 39659738
  • Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fageras M, Cosio BG, Peters M, Pfeffer PE, Al-Ahmad M, Al-Lehebi RO, Altraja A, Bergeron C, Bjermer LH, Bjerrum AS, Bulathsinhala L, Busby J, Cano Rosales DJ, Canonica GW, Carter VA, Charriot J, Christoff GC, Denton EJ, Dorscheid DR, Fernandez Sanchez MJ, Fonseca JA, Gibson PG, Goh CYY, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Lar PMID 38701495
  • Hansen S, Baastrup Sondergaard M, von Bulow A, Bjerrum AS, Schmid J, Rasmussen LM, Johnsen CR, Ingebrigtsen T, Hakansson KEJ, Johansson SL, Bisgaard M, Assing KD, Hilberg O, Ulrik C, Porsbjerg C. Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies. Chest. 2024 Feb;165(2):253-266. doi: 10.1016/j.chest.2023.10.046. Epub 2023 Nov 3. PMID 37925144
  • Holm M, Omenaas E, Gislason T, Svanes C, Jogi R, Norrman E, Janson C, Toren K; RHINE Study Group. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J. 2007 Jul;30(1):62-5. doi: 10.1183/09031936.00121705. Epub 2007 Mar 14. PMID 17360725
  • Almqvist L, Ronmark E, Stridsman C, Backman H, Lindberg A, Lundback B, Hedman L. Remission of adult-onset asthma is rare: a 15-year follow-up study. ERJ Open Res. 2020 Nov 23;6(4):00620-2020. doi: 10.1183/23120541.00620-2020. eCollection 2020 Oct. PMID 33263024

Identifiers

NCT: NCT07328035 · MTU-EC-IM-0-283/68

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗